A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer

Inclusion Criteria:

• Confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease
• Adequate organ and bone marrow function as assessed by laboratory tests
• Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST)
• Agreement to use an effective form of contraception for the duration of the study

Exclusion Criteria:

• History of Grade >/= 3 fasting hyperglycemia
• History of diabetes requiring regular medication
• History of malabsorption syndrome or other condition that would interfere with enteral absorption
• Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agents
• Prior anti-cancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy) within a specified timeframe of the first dose of study treatment
• Uncontrolled current illness
• Active autoimmune disease requiring the equivalent of >10 mg/day of prednisone
• Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus
• Known HIV infection
• New York Heart Association (NYHA) Class II or greater congestive heart failure
• Active ventricular arrhythmia requiring medication
• Pregnancy, lactation, or breastfeeding
• Known significant hypersensitivity to study drugs or excipients
• History of arterial thromboembolic disease within 6 months of first study treatment
• No more than two prior chemotherapy regimens for metastatic disease
• No prior taxane therapy for metastatic disease